Literature DB >> 16738080

To "lump" or to "split" the functional somatic syndromes: can infectious and emotional risk factors differentiate between the onset of chronic fatigue syndrome and irritable bowel syndrome?

Rona Moss-Morris1, Meagan Spence.   

Abstract

OBJECTIVES: Recent academic debate has centered on whether functional somatic syndromes should be defined as separate entities or as one syndrome. The aim of this study was to investigate whether there may be significant differences in the etiology or precipitating factors associated with two common functional syndromes, irritable bowel syndrome (IBS) and chronic fatigue syndrome (CFS).
METHODS: We prospectively studied 592 patients with an acute episode of Campylobacter gastroenteritis and 243 with an acute episode of infectious mononucleosis who had no previous history of CFS or IBS. At the time of infection, patients completed a baseline questionnaire that measured their levels of distress using the Hospital Anxiety and Depression scale. At 3- and 6-month follow-up, they completed questionnaires to determine whether they met published diagnostic criteria for chronic fatigue (CF), CFS, and/or IBS.
RESULTS: The odds of developing IBS were significantly greater post-Campylobacter than post-infectious mononucleosis at both 3- (odds ratio, 3.45 [95% confidence interval (CI), 1.75-6.67]) and 6- (2.22 [95% CI, 1.11-6.67]) month follow-up. In contrast, the odds for developing CF/CFS were significantly greater after infectious mononucleosis than after Campylobacter at 3 (2.77 [95% CI, 1.08-7.11]) but not 6 (1.48 [95% CI, 0.62-3.55]) months postinfection. Anxiety and depression were the strongest predictors of CF/CFS, whereas the nature of the infection was the strongest predictor of IBS.
CONCLUSIONS: These results support the argument to distinguish between postinfectious IBS and CFS. The nature of the precipitating infection appears to be important, and premorbid levels of distress appear to be more strongly associated with CFS than IBS, particularly levels of depression.

Entities:  

Mesh:

Year:  2006        PMID: 16738080     DOI: 10.1097/01.psy.0000221384.07521.05

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  40 in total

1.  Cognitive behavioural model of irritable bowel syndrome.

Authors:  Francis Creed
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

Review 2.  Pain and inflammatory bowel disease.

Authors:  Klaus Bielefeldt; Brian Davis; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

Review 3.  Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions.

Authors:  Lena Ohman; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01-26       Impact factor: 46.802

Review 4.  Post-infectious irritable bowel syndrome.

Authors:  Marroon Thabane; John K Marshall
Journal:  World J Gastroenterol       Date:  2009-08-07       Impact factor: 5.742

5.  A population-based twin study of functional somatic syndromes.

Authors:  K Kato; P F Sullivan; B Evengård; N L Pedersen
Journal:  Psychol Med       Date:  2008-06-26       Impact factor: 7.723

Review 6.  Psychogenic nonepileptic seizures and movement disorders: A comparative review.

Authors:  Roberto Erro; Francesco Brigo; Eugen Trinka; Giulia Turri; Mark J Edwards; Michele Tinazzi
Journal:  Neurol Clin Pract       Date:  2016-04

Review 7.  Global Epidemiology of Campylobacter Infection.

Authors:  Nadeem O Kaakoush; Natalia Castaño-Rodríguez; Hazel M Mitchell; Si Ming Man
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

8.  The medically unexplained revisited.

Authors:  Thor Eirik Eriksen; Anna Luise Kirkengen; Arne Johan Vetlesen
Journal:  Med Health Care Philos       Date:  2013-08

9.  Gut inflammation in chronic fatigue syndrome.

Authors:  Shaheen E Lakhan; Annette Kirchgessner
Journal:  Nutr Metab (Lond)       Date:  2010-10-12       Impact factor: 4.169

10.  High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection.

Authors:  A Wadhwa; M F Al Nahhas; R A Dierkhising; R Patel; P Kashyap; D S Pardi; S Khanna; M Grover
Journal:  Aliment Pharmacol Ther       Date:  2016-07-22       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.